For patients with an A1C of 6.5% to 7.5%, metformin is the preferred initial agent, with GLP-1 receptor agonists, dipeptidyl-peptidase-4 (DPP-4) inhibitors, thiazolidinediones (TZDs), or an alpha-glucosidase inhibitor listed as viable alternatives
We are currently accepting Ozempic lawsuit cases specifically related to gastroparesis, a life-altering condition linked to the drugs use
You want to know youre working with a provider who listens, understands your goals, and genuinely cares about helping you move toward sustainable weight loss
Semaglutide also has a longer half-life than the older GLP-1s and may have a stronger effect on receptors in the brain, which could help explain the difference in findings, Moreno adds
More than 215 had been reported for tirzepatide
There is no retail distribution, and the platform is not available through third-party pharmacies or marketplaces